Dopamine turnover and glutathione oxidation: implications for Parkinson disease
about
Biomarkers of manganese intoxicationUnderstanding the human health effects of chemical mixtures.Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathwaysMethamphetamine effects on blood-brain barrier structure and functionAging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's diseaseTranscriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction.Testosterone Propionate Exacerbates the Deficits of Nigrostriatal Dopaminergic System and Downregulates Nrf2 Expression in Reserpine-Treated Aged Male RatsNew Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice.CNB-001 a novel curcumin derivative, guards dopamine neurons in MPTP model of Parkinson's disease.Catecholamine oxidative products, but not melanin, are produced by Cryptococcus neoformans during neuropathogenesis in mice.Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease.Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleusSustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis.Potentiation of N-methyl-D-aspartate receptor-mediated neuronal injury during methamphetamine withdrawal in vitro requires co-activation of IP3 receptors.Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patientsPotent induction of total cellular GSH and NQO1 as well as mitochondrial GSH by 3H-1,2-dithiole-3-thione in SH-SY5Y neuroblastoma cells and primary human neurons: protection against neurocytotoxicity elicited by dopamine, 6-hydroxydopamine, 4-hydroxAnalysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease.Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flowRadical-free biology of oxidative stress.Stress as a modulator of motor system function and pathology.The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease.Role of glycogen synthase kinase-3 in l-DOPA-induced neurotoxicity.Psychological Stress and Changes of Hypothalamic-Pituitary-Adrenal Axis in Patients with "De Novo" Parkinson's DiseaseDelayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons.Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology.Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.Down-regulation of apurinic/apyrimidinic endonuclease 1 (APE1) in spinal motor neurones under oxidative stress.Neuroprotective effects of the drug GVT (monosodium luminol) are mediated by the stabilization of Nrf2 in astrocytesMelanogenesis and the generation of cytotoxic molecules during insect cellular immune reactions.Brain mitochondrial drug delivery: influence of drug physicochemical properties.Antidyskinetic drug therapy for pediatric movement disorders.A Disposable Microfluidic Device with a Screen Printed Electrode for Mimicking Phase II Metabolism.Passiflora cincinnata Extract Delays the Development of Motor Signs and Prevents Dopaminergic Loss in a Mice Model of Parkinson's Disease.In vitro and in vivo protective effects of melatonin against glutamate oxidative stress and neurotoxicity.Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update.Modulatory role of glutathione on mu-opioid, substance P/neurokinin-1, and kainic acid receptor binding sites.Disease progression, drug action and Parkinson's disease: why time cannot be ignored.
P2860
Q23923587-73FA20C0-750C-40CA-856C-8B4CE1E432CBQ24811691-2124FA09-E69F-4A50-8150-65473D671B8AQ26779424-0289D887-E70A-4D42-9021-45CB25EF29A0Q26825795-C364686A-C538-4FA1-BCC7-7AF2454E9D6FQ28324372-803BB3FD-8CC7-4CE7-98F7-44E4BDDDF81BQ30301131-46B17014-F253-4FEB-9379-51091B09A2DCQ33740665-53BFC53E-BF7B-4128-BD63-29F6C449CBA1Q33783000-E33B3771-506A-4FC8-A9F2-1DCA3A1AC2F5Q33797938-E9A8C913-4D2C-444E-9920-B2ACBD93E2FCQ33851011-71A00F2C-CA07-4F84-BB16-E5C11A274A52Q33999899-E1FD0BEA-E936-434E-AA80-5CE36A03F847Q34141266-1D6C9485-DBFB-4DD2-B023-87889F907986Q34360660-BAC56310-6CF9-4D1C-8ACA-486EA599106BQ35856269-9A83A195-03CA-4227-9270-97D284E249DCQ36061821-A403B0BF-0109-4CC9-A732-7A11056575B9Q36301391-D16DB835-9707-4C10-AAB8-0AB9B00C1A18Q36340654-60587FFA-76D3-469E-990F-991A11DD88FBQ36424253-5FDA3188-7583-426F-B297-18041105AF9FQ36662810-53E6B88A-D047-4411-9684-AEB165FAC24CQ36708352-6CE67E34-FA4A-48C8-8E7E-73C8789A6BEAQ36762569-9A0D0548-EA31-4662-A6FD-4F47F9DA754DQ36955833-8D1DC37F-4097-4E42-AD03-320F7118E88BQ37003952-DC46BF07-FC53-4BC0-A838-13127F1293F5Q37248671-61E10E3B-DCDB-4200-832D-F0573D37BF20Q37575513-582CC773-0F05-4008-9BC0-50409D3E5381Q37625021-A48E1981-33AE-486E-8416-C8D14DD483CCQ37710820-35C3EACE-BA68-4C25-86B9-7567CD64FC72Q38101508-7B92A942-A769-4038-981E-60E391839FEBQ38366271-B3A87696-DC2C-4138-BE47-E6CC2F5A1F78Q39133838-894FD853-DC8A-4F12-B0E2-A8A95D53C905Q39730979-6279C592-AFE6-42F5-AF38-06775C075416Q40777069-CBE3BB39-7BA9-4E90-A404-B30DDAA18DC3Q41015003-E63C2846-E51D-4152-B96C-C6E01024F7D9Q41172780-2E789E51-E110-46C6-BC63-DDE32DFF6F45Q41197069-D32B9547-CB03-4E51-BDE0-1498266934D2Q41395526-7924981E-D8AF-48EA-8E26-92ACD130310FQ41643090-8FA662CE-CC48-4390-99B6-3E851C4F156FQ41680664-D84BC30C-D178-4497-A65A-E335193D8D66Q41877472-DD6BE8FC-5EBC-4116-81CA-8798930CF535Q42226525-831018E3-1D03-4C9A-A182-E566D8BF4480
P2860
Dopamine turnover and glutathione oxidation: implications for Parkinson disease
description
1989 nî lūn-bûn
@nan
1989 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Dopamine turnover and glutathione oxidation: implications for Parkinson disease
@ast
Dopamine turnover and glutathione oxidation: implications for Parkinson disease
@en
type
label
Dopamine turnover and glutathione oxidation: implications for Parkinson disease
@ast
Dopamine turnover and glutathione oxidation: implications for Parkinson disease
@en
prefLabel
Dopamine turnover and glutathione oxidation: implications for Parkinson disease
@ast
Dopamine turnover and glutathione oxidation: implications for Parkinson disease
@en
P2860
P356
P1476
Dopamine turnover and glutathione oxidation: implications for Parkinson disease
@en
P2093
P2860
P304
P356
10.1073/PNAS.86.4.1398
P407
P577
1989-02-01T00:00:00Z